Comparison of Tolerability Between Two Allergy Drops
Phase 4
- Conditions
- Allergic Conjunctivitis
- Registration Number
- NCT01390961
- Lead Sponsor
- Hom, Milton M., OD, FAAO
- Brief Summary
Comfort is compared between two allergy drops
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Between the ages of 18 and over inclusive.
- Males or females
- Patient is in generally good & stable overall health.
- Patient likely to comply with study guidelines & study visits.
- Informed consent signed.
- History of allergic conjunctivitis
- Current symptoms of allergic conjunctivitis assessed by the investigator
Exclusion Criteria
- Corneal refractive surgery or contact lens wear within 6 months of this study.
- Current use of Restasis
- Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.
- Pregnant or lactating women.
- Ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Tolerability 8 weeks Tolerability measured by questionnaire Visual Analog scale 1 to 100
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate the two allergy drops in NCT01390961 for allergic conjunctivitis?
How does the tolerability of NCT01390961 allergy drops compare to standard-of-care antihistamines for allergic conjunctivitis?
Are there specific biomarkers that correlate with improved tolerability in allergic conjunctivitis patients using allergy drops?
What adverse events are associated with allergy drop therapies for allergic conjunctivitis and how are they managed?
What are the potential advantages of combination therapies involving allergy drops for allergic conjunctivitis compared to monotherapy?
Trial Locations
- Locations (1)
Milton M. Hom, OD, FAAO.
🇺🇸Azusa, California, United States
Milton M. Hom, OD, FAAO.🇺🇸Azusa, California, United States